Cantero Therapeutics

Cantero Therapeutics is a private BridgeBio-affiliated biotechnology company focused on small-molecule therapies for rare metabolic and kidney disorders. Publicly visible evidence ties the company to development of oral glycolate oxidase inhibitors, including BBP-711/ORF-229, also referred to as vamagloxistat in some databases. Its lead program has been studied in a Phase 1 healthy-volunteer trial and has been positioned for disorders such as primary hyperoxaluria type 1 and recurrent kidney stone disease. Patent filings assigned to the company describe triazole and related glycolate oxidase inhibitor chemistries for lowering oxalate. Overall, Cantero appears to function as a focused subsidiary or affiliate vehicle within the broader BridgeBio network rather than as a diversified standalone commercial-stage biotech.